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vThe two human polyomaviruses, BKV and JCV, have
lived much of their lives in the shadows of their more
intensively studied simian and murine cousins, SV40 and
Py. JCV and BKV are primarily associated with progres-
sive multifocal leukoencephalopathy (PML) and hemor-
rhagic cystitis, respectively, and a role for these viruses
in human cancer has been suggested. In this review, I
will present a historical overview of the viruses, briefly
describe new developments in our understanding of the
molecular pathogenesis of the diseases in which viral
involvement is clearly implicated, and then discuss what
is known about the potential role of these viruses in
human cancer. The reader is referred to a series of more
comprehensive reviews (Raj and Khalili, 1995; Dorries,
1997, 1998; Gallia et al., 1997; Weber and Major, 1997;
arbanti-Brodano et al., 1998), as well as to the primary
iterature cited herein, for more details.
BKV and JCV were first isolated in 1971, the former from
he urine of a renal transplant patient and the latter from
he brain of a patient with PML (Gardner et al., 1971;
adgett et al., 1971). Both viruses are found at high
requencies throughout most human populations. Pri-
ary infection with BKV occurs early in childhood, while
CV seroconversion occurs slightly more toward adoles-
ence (Gardner, 1973; Padgett and Walker, 1973; Taguchi
t al., 1982). Initial infection is inapparent and rarely
auses clinical disease, although respiratory symptoms
r urinary tract disease are sometimes found in the case
f BKV (Hashida et al., 1976; Goudsmit et al., 1981; Min-
inberg et al., 1982; Padgett et al., 1983). BKV and JCV can
be detected in tonsillar tissue from both pediatric and
adult donors (Goudsmit et al., 1982; Monaco et al., 1998),
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1and it has been reported that JCV can replicate in ton-
sillar B lymphocytes and stromal cells (Monaco et al.,
1996), supporting the notion that the respiratory tract is
the primary site of viral infection. It is thought that the
main route of spread between individuals is through
respiratory secretions during this acute phase of infec-
tion. After the initial infection, the virus disseminates and
establishes a persistent infection in the urinary tract,
lymphocytes, and in the case of JCV, the brain.
JCV strains fall into two groups, designated archetypal
and rearranged, based on the structure of their transcrip-
tional control regions (TCRs). The TCR of archetype JCV
contains a single copy of the promoter and enhancer,
while the rearranged strains contain deletions and du-
plications in this region (Yogo et al., 1990, 1991; Ault and
Stoner, 1993). The archetype strains are believed to be
the viruses that spread throughout the population and
establish persistent infections, as they can be isolated
from both normal individuals and immunocompromised
patients (Yogo et al., 1990; Flaegstad et al., 1991;
Markowitz et al., 1991; Tominaga et al., 1992; White et al.,
992; Ault and Stoner, 1993; Kitamura et al., 1994; Kuni-
ake et al., 1995; Guo et al., 1996; Agostini et al., 1996;
ugimoto et al., 1997; Ciappi et al., 1999). Rearranged
trains of the virus have been isolated from brain, kidney,
nd lymphocytes of PML patients, as well as from brain,
SF, and lymphocytes of nonaffected individuals (Martin
t al., 1985; Loeber and Dorries, 1988; White et al., 1992;
ult and Stoner, 1993; Dorries et al., 1994; Kato et al.,
994; Yogo et al., 1994; Elsner and Dorries, 1998; Ciappi
t al., 1999; Newman and Frisque, 1999). The duplicated
egions include the binding sites for a variety of tran-
cription factors (see below). Thus, it is believed that
hese rearrangements lead to altered transcription pat-
erns of the early region, which could affect the level of
iral replication and ultimately cause disease. Note,
owever, that the correlation between TCR structure and
isease state is not exact: while the rearranged strains
0042-6822/00 $35.00
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2 MINIREVIEWfound in PML lesions appear to be derived from arche-
typal strains isolated from the same individuals, as
stated above rearranged strains can also be isolated
from individuals with no apparent disease. The simplest
explanation is that there are host factors that contribute
to the ability of the virus to cause disease, and these
likely differ among individuals or even within a given
person over the person’s lifetime. Although BKV has not
been studied in as much detail, isolates of this virus also
appear to fall into the same two general classes, arche-
typal and rearranged (Rubinstein et al., 1987, 1991; Ne-
rini et al., 1991). Infection by both viruses is kept in
check by the immune system, with reactivation occurring
mainly in immunocompromised individuals such as
transplant recipients, pregnant women, or AIDS patients.
PML is a neurodegenerative disease that is clearly
caused by JCV infection (Weber and Major, 1997). Cell
destruction is thought to be carried out by the lytic
replication of the virus in oligodendrocytes, which are
myelin-producing cells in the brain. Currently, it is not
known when during the course of natural infection or
how the virus gets into the CNS. Replication of the virus
is controlled primarily at the transcriptional level, and a
great deal of effort has gone into defining the factors that
seem to allow for tissue-specific replication of the virus.
As discussed above, the rearrangements in the TCR are
thought to contribute to the increased replication capac-
ity of the virus in the brain (Daniel et al., 1996). It has
been demonstrated that transcription of the early region
and, therefore, expression of the major viral regulatory
protein, large T antigen, is driven by a constellation of
transcription factors that interact with the early promoter
elements in the TCR (Major et al., 1990; Frisque and
White, 1992; Raj and Khalili, 1995). These factors include
Tst-1, NF-1, Sp1, GBPi, NF-kB, YB-1, Pura, and GF-1, which
ogether determine the tropism of JCV to glial cells in the
rain (Khalili et al., 1988; Tada et al., 1989; Major et al.,
990; Kerr and Khalili, 1991; Feigenbaum et al., 1992;
enson et al., 1992; Ranganathan and Khalili, 1993; Weg-
er et al., 1993; Kerr et al., 1994; Raj and Khalili, 1994;
hen et al., 1995; Chen and Khalili, 1995; Raj et al., 1996;
hang et al., 1996; Safak et al., 1999). It is notable that
one of these factors is expressed solely in glial cells,
lthough Pura DNA-binding activity is detectable only in
rain and not in other tissues in which the gene is known
o be expressed. It will be interesting to see which
actors govern the ability of JCV to replicate in lympho-
ytes and stromal cells in the tonsils. Once these tran-
cription factors cooperate to induce early region ex-
ression, T antigen accumulates, binds to the viral origin
f DNA replication, and allows for amplification of the
enome, expression of the late genes, and completion of
he life cycle of the virus. There is also evidence that the
unction of JCV T antigen itself may be restricted to glial
ells (Lynch and Frisque, 1991), and it is also possible
hat the ability of T antigen to interact with some of theellular factors described above influences cell type
pecificity (Gallia et al., 1998; Sock et al., 1999).
Less is known about the molecular aspects of how
KV contributes to hemorrhagic cystitis in the bladder,
hich can also be caused by adenovirus infection. It can
e inferred from the incidence of this disease in immu-
ocompromised patients that normally the immune sys-
em keeps viral replication in check. As is the case for
CV in the brain, it is likely that the pathology of the
isease is caused by viral destruction of cells in the
ladder, in this case endothelial cells. Whether there is a
eservoir of BKV in the bladder that reactivates upon
mmunosuppression, or whether it moves there from the
idney at that point in time, is not clear, although there is
ome evidence of BKV in normal bladder (Monini et al.,
995b). The type of detailed analysis that has gone into
lucidating transcriptional regulation of JCV expression
as not been performed on BKV. What is known, how-
ver, is that multiple transcription factors interact with
he viral promoter and enhancer (Chakraborty and Das,
989; Ferguson and Subramani, 1994); rearrangements
ccur during passage in culture (Watanabe and Yoshiike,
982; Rubinstein et al., 1991) and, as mentioned above, in
vivo (Negrini et al., 1991); and such rearrangements can
sometimes create new binding sites for other transcrip-
tion factors (Markowitz et al., 1990).
It is fair to state that there is no conclusive proof that
either of the human polyomaviruses directly causes or
acts as a cofactor in human cancer, although evidence
implicating the two viruses in various types of human
tumors has accumulated over the years. Specifically,
investigators have looked for the presence of viral se-
quences and the expression of T antigen in a variety of
neoplasms. The analysis is complicated by the fact that
both viruses are ubiquitous in the population: definitive
proof will require the demonstration of meaningful mo-
lecular changes in the lifestyle of the virus between
normal and abnormal cells.
One might expect to find an association of JCV with
various CNS tumors due to the presence of factors that
activate T antigen expression. Indeed, there have been
reports of JCV variants in a variety of human brain tu-
mors, but these studies have not, to date, demonstrated
any causal effects. Interestingly, when newborn ham-
sters are inoculated intracerebrally, intraperitoneally, or
subcutaneously with JCV(Mad), a rearranged strain of
the virus, they too develop neurological tumors (Walker
et al., 1973; ZuRhein, 1983), and transgenic mice ex-
pressing the JCV(Mad) early region develop adrenal neu-
roblastomas (Small et al., 1986) or poorly differentiated
tumors of possible neuroectodermal origin (Franks et al.,
1996). Most recently, transgenic mice expressing the
early region of an archetype strain of JCV were derived.
About half of the mice analyzed demonstrated neurologic
illness at 9–13 months of age, and pathological analysis
determined that while these mice had no apparent ab-
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3MINIREVIEWnormalities in glial cells or myelin production, they did
develop primitive neuroectodermal tumors (Krynska et
al., 1999). The tumor cells expressed higher levels of T
ntigen than did cells in the hindbrains of normal trans-
enic mice. As a follow-up to these studies, Khalili’s
roup has examined human medulloblastomas for the
resence of JCV using PCR and in situ immunohisto-
chemical analyses (Khalili et al., 1999). Although only a
small number of tumors were examined (11), 8 of these
were positive for early region sequences and 10 were
positive for the late region. Immunohistochemical analy-
sis demonstrated staining for T antigen but not for VP1,
one of the viral capsid proteins, in 5–20% of the tumor
cells from roughly 14 of the PCR-positive samples. This
esult would indicate that lytic replication is not occurring
lthough T antigen is being expressed. Such a switch in
he life cycle of the virus would be required for oncogenic
ransformation of the cell, as a productive infection would
ill the cell even if its growth were abnormal.
With respect to BKV, there is also correlative evidence
egarding its potential role in cancer. As is the case for
CV, BKV induces tumors in experimental animals: trans-
enic mice expressing BKV develop hepatocellular car-
inoma and renal tumors (Small et al., 1986; Dalrymple
nd Beemon, 1990). There have been a number of re-
orts demonstrating the presence of BKV sequences in a
ariety of human tumors, including brain, pancreas, rhab-
omyosarcoma, lung, liver, Kaposi’s sarcoma, and vari-
us urinary tract neoplasms (Fiori and Di Mayorca, 1976;
ater et al., 1980; Caputo et al., 1983; Dorries et al., 1987;
arbanti-Brodano et al., 1987; Corallini et al., 1987; Ne-
rini et al., 1990; De Mattei et al., 1995; Monini et al.,
995a,b, 1996; Flaegstad et al., 1999), although one re-
ort found no evidence for BKV in brain tumors (Arthur et
l., 1994). It is the study by Monini et al. (1995b) that lends
he most support to a possible causative role of BKV in
ancer. These investigators demonstrated that BKV se-
uences could be detected by PCR analysis in both
ormal and tumor tissue isolated from the urinary tracts
f greater than half the patients examined. Since BKV
nfection is widespread, this prevalence is not surprising
or is the location, since BKV persists in the kidney and
herefore has access to the rest of the urinary tract. The
ntriguing part of this report, however, was that viral
equences could be detected by Southern blotting in six
f the tumor samples, but none of the normal tissues.
his could be explained in two ways: either there is
mplification of the viral chromosome in the tumor or
here is selection in the tumor for cells containing BKV.
he latter explanation appears to be correct, as further
nalysis indicated that the viral sequences were inte-
rated into the host chromosome in all six tumors exam-
ned, although one contained episomal copies as well.
oreover, these authors determined the sequences ofhe viral origin regions from nine of the abnormal tissues.
hey found that all the sequences were identical except
a
1or two point mutations in one of the samples, and these
epresented a new strain of BKV, which they designated
RO1. It is intriguing that this strain contains rearrange-
ents in the origin region, as these might affect viral
NA replication. It is known, for example, that disrup-
ions in this region alter replication ability and increase
ransformation potential in cell culture assays (Watanabe
nd Yoshiike, 1982, 1985; Rubinstein et al., 1991). Also, as
iscussed above, such rearrangements could alter the
ranscriptional specificity of the promoter. Clearly, a
lock to replication would prevent killing of the host cell
nd rather lead to transformation if T antigen were to be
xpressed continually, much the same as that which
ccurs during transformation of nonpermissive cells by
ild-type polyomaviruses (Butel, 1986) or of permissive
ells by viral chromosomes whose origin of replication
as been mutated (Gluzman, 1981). Whether the muta-
ions in URO1 have this same effect on replication or
ransformation remains to be determined.
BKV and JCV T antigens, like SV40 T antigen, interact
ith tumor suppressor proteins in the cell in order to
ptimize the environment for viral replication. These T
ntigens transform rodent cells in culture and can also
mmortalize human cells in the presence of activated
ncogenes such as ras or myc (Shah et al., 1976; Porto-
ani et al., 1978; Purchio and Fareed, 1979; Takemoto et
l., 1979; Frisque et al., 1980; Howley et al., 1980; Grossi
t al., 1982; Pater and Pater, 1986), although JCV does so
elatively poorly (Bollag et al., 1989; Haggerty et al., 1989;
rowbridge and Frisque, 1993; Tavis et al., 1994). Both
KV and JCV T antigens bind to pRb (retinoblastoma
usceptibility) family proteins and p53 (Dyson et al., 1989,
990; Bollag et al., 1989; Trowbridge and Frisque, 1993;
arris et al., 1996). As is the case for SV40 T antigen,
inding of BKV T antigen to p53 stabilizes the p53 but
nterferes with its response to DNA damaging agents
Harris et al., 1998a). The interaction of BKV T antigen
ith the pRb family proteins, however, is somewhat dif-
erent than that of SV40 T antigen (Harris et al., 1996,
998b). In cells expressing BKV T antigen, it is difficult to
etect significant amounts of complexes between T an-
igen and pRb, p107, or p130. This is because the levels
f T antigen expressed from the BKV early promoter are
ery low. Nevertheless, BKV T antigen does stimulate
elease of E2F activity from pRb family complexes and
llows for serum-independent growth. Mutational analy-
is of BKV T antigen has demonstrated that the activation
f E2F requires both the pRb-binding domain and a
ewly defined N-terminal domain of the molecule called
he J domain. This domain gets its name based on
tructural and functional homology to the DnaJ family of
olecular chaperones and mediates a number of impor-
ant T antigen functions related to transcription, replica-
ion, and transformation (Campbell et al., 1997; Stubdal et
l., 1997; Kelley and Georgopoulus, 1997; Zalvide et al.,
998; Brodsky and Pipas, 1998; Harris et al., 1998b; Sock
4 MINIREVIEWet al., 1999). The model that has been proposed for how
this domain functions in oncogenic transformation is that
T antigen interacts with the pRb family protein, causing
release of E2F and subsequent J domain-mediated deg-
radation of the pRb family protein. BKV and SV40 T
antigens differ in two ways: first, BKV T antigen causes
the degradation of all three pRb family members while
SV40 T antigen affects only p107 and p130, and second,
part of the effect of SV40 T antigen does appear to be
due to high enough levels of T antigen to physically
sequester the pRb family members, while the BKV effect
appears to be mediated solely through the J domain
function (Zalvide et al., 1998; Harris et al., 1998b). Al-
though they do bind each other, the consequences of the
interaction between JCV T antigen and the pRb family
proteins have not been studied in as much detail, so at
this time it is unclear exactly how JCV T antigen inter-
feres with the function of these tumor suppressor pro-
teins. Nevertheless, JCV T antigen does deregulate cy-
clin/Cdk (cyclin-dependent kinase) activity and blocks
exit from the cell cycle (Tretiakova et al., 1999). Finally,
both BKV and JCV T antigens induce chromosomal ab-
errations in cultured cells (Theile and Grabowski, 1990;
Tognon et al., 1996; Neel et al., 1996; Trabanelli et al.,
1998) (K. F. Harris, T. Glover, and M. J. Imperiale, unpub-
lished results), and increased chromosomal damage
correlates with high titers of antibodies against the vi-
ruses (Lazutka et al., 1996). Thus, T antigen induces
inappropriate cell growth through its interactions with
pRb family proteins, is mutagenic, and interferes with the
ability of the cell to respond to damaged DNA through its
interaction with p53. Taken together, it is clear that JCV
and BKV T antigen have the molecular characteristics to
contribute to the oncogenic process. A more detailed
molecular analysis will be required before a role for BKV
and JCV in human cancer can be confirmed or refuted,
but obtaining proof will be complicated by the fact that a
large percentage of the population is infected with these
viruses. Thus, in analyzing tumor samples, one must be
fairly certain that one is examining only tumor cells and
not contaminating normal cells from surrounding tissue,
especially when using sensitive techniques such as PCR
or RT-PCR.
A final related issue that needs to be mentioned in the
context of human cancer and polyomaviruses is the
possibility that SV40, too, is involved in a subset of
human cancers (see (Levine et al., 1998; Barbanti-Bro-
dano et al., 1998) for recent reviews). SV40 sequences
and T antigen expression have been detected in me-
sotheliomas, osteosarcomas, and brain tumors; not sur-
prisingly, this is the same spectrum of tumors induced by
SV40 in animal models. Curiously, one of the first reports
of SV40 in human tumors came out of a study in which
the investigators were searching for BKV or JCV and
were using an SV40 probe as a negative control (Berg-
sagel et al., 1992). As some of these tumors were ob-tained from patients whose age excludes them from the
pool of individuals who received the contaminated lots of
poliovirus vaccines in which SV40 was first discovered,
these data indicate that SV40 may be transmitted
throughout the human population, in effect making it a
third human polyomavirus. That being the case, the
wealth of knowledge that has accumulated regarding the
mechanisms of oncogenesis by SV40 would become all
the more relevant to BKV and JCV, although it could also
mean that these two viruses may never, and perhaps
should never, completely escape from SV40’s shadow.
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